SLN Silence Therapeutics plc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1479615
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-98.2%
TTM net income YoY20.3%
TTM EPS YoY22.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin95.0%
Operating margin-12,343.6%
Net margin-11,276.5%
FCF margin-9,681.6%
EBITDA margin-12,279.2%
Returns
ROE-35.6%
ROA-24.0%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets23.6%
Debt / equity0.00x
Current ratio23.94x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.86x
Accruals ratio-3.4%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 · USD | FY20242024-12-31 · USD | FY20232023-12-31 · USD | FY20222022-12-31 · GBP | FY2021*2021-12-31 · GBP |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $559,000 | $43.26M | $31.64M | 17.50M | 12.41M |
| Cost of revenue | $215,000 | $11.81M | $12.87M | 10.88M | 7.46M |
| Gross profit | $344,000 | $31.45M | $18.78M | 6.62M | 4.96M |
| R&D expense | $67.75M | $67.88M | $56.94M | 35.60M | 30.77M |
| SG&A expense | $22.34M | $26.88M | $26.22M | 19.61M | 20.01M |
| Operating income | -$91.08M | -$63.32M | -$64.38M | -48.59M | -45.81M |
| Interest expense | — | — | 2.15MGBP | 47,000 | 52,000 |
| Pretax income | -$88.60M | -$44.46M | -$53.27M | -47.37M | -45.86M |
| Income tax | $11,000 | $845,000 | $956,000 | -6.88M | -6.45M |
| Net income | -$88.61M | -$45.31M | -$54.23M | -$50.33MUSD | -39.41M |
| EBITDA | -$90.77M | -$62.98M | -$64.01M | — | — |
| EPS (basic) | -0.63 | -0.33 | -0.49 | -0.52USD | — |
| EPS (diluted) | -0.63 | -0.33 | -0.49 | -0.52USD | — |
| Weighted avg. shares (diluted) | 141.69M | 138.75M | 111.28M | 96.58M | — |
| Banking | |||||
| Net interest income | — | — | 67,000GBP | 23,000 | 10,000 |
| Balance sheet | |||||
| Cash & equivalents | $11.28M | $121.33M | $68.79M | 54.82M | 73.54M |
| Short-term investments | $73.84M | $26.00M | — | — | — |
| Receivables | $0 | $972,000 | $290,000 | 915,000 | 331,000 |
| Current assets | $118.66M | $187.37M | $103.15M | 96.69M | 86.33M |
| PP&E, net | $1.58M | $1.82M | $1.94M | 2.20M | 1.94M |
| Goodwill | $10.62M | $9.39M | $9.98M | 8.01M | 7.59M |
| Intangibles | $288,000 | $312,000 | — | — | — |
| Total assets | $131.44M | $202.63M | $119.45M | — | — |
| Current liabilities | $13.61M | $16.82M | $22.34M | 21.94M | 15.17M |
| Total liabilities | $69.14M | $68.61M | $97.45M | — | — |
| Shareholders' equity | $62.30M | $134.02M | $21.99M | $27.22MUSD | $12.37MUSD |
| Shares outstanding | 141.70M | 141.67M | 118.85M | 107.81M | — |
| Cash flow statement | |||||
| Operating cash flow | -$62.27M | -$67.64M | -$49.46M | -45.46M | 6.81M |
| Capital expenditure | $55,000 | $211,000 | $56,000 | 140,000 | 1.31M |
| Free cash flow | -$62.33M | -$67.85M | -$49.52M | -45.60M | 5.50M |
| Investing cash flow | -$47.99M | -$21.97M | $19.29M | -16.54M | 8.68M |
| Financing cash flow | $15,000 | $142.09M | $31.94M | 43.05M | 30.71M |
| Depreciation & amortization | $312,000 | $336,000 | $369,000 | $379,000USD | — |
| Stock-based compensation | $8.07M | $16.31M | $16.27M | 10.25M | 8.63M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.